An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study
Siqi Li, Lan‐Ping Xu, Yu Wang, Xiaohui Zhang, Huan Chen, Yu‐Hong Chen, Feng‐Rong Wang, Wei Han, Yuqian Sun, Chen-Hua Yan, Meng Lv, Feifei Tang, Xiao‐Dong Mo, Yanrong Liu, Kai‐Yan Liu, Ying‐Jun Chang, Xiao‐Jun Huang
Abstract
Li et al delineate a novel technique for assessing measurable residual disease (MRD) by the assessment of isolated leukemia stem cells (LSCs). They report that assessment of MRD in LSCs provides a better prediction of outcome than standard multiparameter flow cytometry.
Topics & Concepts
Minimal residual diseaseOncologyMedicineFlow cytometryLeukemiaInternal medicineImmunologyAcute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationImmune cells in cancer